Essex Investment Management Co. LLC trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 22.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 125,381 shares of the biopharmaceutical company’s stock after selling 35,508 shares during the period. Essex Investment Management Co. LLC’s holdings in Amicus Therapeutics were worth $1,804,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Alliancebernstein L.P. increased its holdings in shares of Amicus Therapeutics by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock valued at $2,073,000 after acquiring an additional 28,800 shares during the period. Bank of Nova Scotia acquired a new position in Amicus Therapeutics in the 2nd quarter valued at $1,944,000. American International Group Inc. increased its stake in Amicus Therapeutics by 23.1% in the 3rd quarter. American International Group Inc. now owns 109,628 shares of the biopharmaceutical company’s stock valued at $1,653,000 after buying an additional 20,597 shares during the period. Vanguard Group Inc. increased its stake in Amicus Therapeutics by 5.0% in the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after buying an additional 430,486 shares during the period. Finally, State Street Corp increased its stake in Amicus Therapeutics by 2.2% in the 2nd quarter. State Street Corp now owns 5,892,564 shares of the biopharmaceutical company’s stock valued at $59,332,000 after buying an additional 125,635 shares during the period.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $16.35 on Wednesday. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. Amicus Therapeutics, Inc. has a 12 month low of $5.82 and a 12 month high of $17.40.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The company had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. During the same period last year, the company earned ($0.33) earnings per share. The business’s revenue for the quarter was up 419.0% compared to the same quarter last year. equities research analysts forecast that Amicus Therapeutics, Inc. will post -1.52 earnings per share for the current year.

In other news, CEO John F. Crowley sold 5,920 shares of the company’s stock in a transaction on Saturday, December 29th. The shares were sold at an average price of $14.75, for a total transaction of $87,320.00. Following the transaction, the chief executive officer now directly owns 341,051 shares of the company’s stock, valued at approximately $5,030,502.25. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO John F. Crowley sold 65,581 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $13.51, for a total transaction of $885,999.31. Following the transaction, the chief executive officer now directly owns 393,076 shares in the company, valued at $5,310,456.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 250,390 shares of company stock worth $3,620,581. Corporate insiders own 3.40% of the company’s stock.

Several equities analysts have issued reports on FOLD shares. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. Cowen reissued a “buy” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, January 15th. Finally, ValuEngine raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Amicus Therapeutics presently has a consensus rating of “Buy” and an average price target of $18.31.

WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/02/07/amicus-therapeutics-inc-fold-stake-decreased-by-essex-investment-management-co-llc.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.